Mankind Pharma

BSE: 543904 | NSE: MANKIND | ISIN: INE634S01028 | SECTOR: -

₹ 2,360.00

-38.80 (-1.62%)
26 Apr 2024, 03:29 PM IST
View all metrics

Key Metrics

Influencer Count

-

Simple Moving Averages

DaysBSENSE

52,350.632,350.57
102,342.662,343.32
202,318.672,321.06
502,222.452,223.62
1002,120.292,121.00
3001,961.121,961.56

News

View all

Company Description

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Company Officers